CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft
More Information Supplier PageCB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft
More Information Supplier PageCB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft
More Information Supplier PageCC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCiproxifan is an extremely potent histamine H3 inverse agonist/antagonist.
More Information Supplier PageCiproxifan is an extremely potent histamine H3 inverse agonist/antagonist.
More Information Supplier PageCZC24832 is a selective inhibitor of PI 3-Kinase ?? (IC50 = 1.0 ??M in a PI 3-K??-dependent fMLP-induced neutrophil migration assay).
More Information Supplier PageCZC24832 is a selective inhibitor of PI 3-Kinase ?? (IC50 = 1.0 ??M in a PI 3-K??-dependent fMLP-induced neutrophil migration assay).
More Information Supplier Page
